. inCVAX belongs to a new class of therapeutics that utilize intratumoral injections intended to induce customized immune activation against a patient’s own, unique cancer. In initial clinical studies, several breast cancer patients experienced shrinkage of both local tumors and distant metastases following inCVAX treatment. In some cases, this led to a complete, long-term response. Our first clinical trial in Switzerland, is a clear path forward to gain clinical evidence in additional indications.
IPS Biopharma is a biotech company developing a proprietary drug for use in the innovative cancer immunotherapy inCVAX for the treatment of solid metastatic tumors.